Compare · CBOE vs PBIO
CBOE vs PBIO
Side-by-side comparison of Cboe Global Markets, Inc. (CBOE) and Pressure BioSciences, Inc. (PBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBOE and PBIO operate in n/a (n/a), so they compete in similar markets.
- CBOE carries a market cap of $13.01B.
- CBOE has hit the wire 12 times in the past 4 weeks while PBIO has been quiet.
- CBOE has more recent analyst coverage (25 ratings vs 0 for PBIO).
Cboe Global Markets, Inc.
Cboe Global Markets, Inc., through its subsidiaries, operates as an options exchange worldwide. It operates through five segments: Options, North American Equities, Futures, European Equities, and Global FX. The Options segment trades in listed market indices. The North American Equities segment trades in listed U.S. and Canadian equities; and offers exchange-traded products (ETP) transaction and ETP listing services. The Futures segment trades in futures. The European Equities segment offers pan-European listed equities transaction services, ETPs, exchange-traded commodities, and international depository receipts, as well as ETP listings and clearing services. The Global FX segment provides institutional foreign exchange (FX) trading and non-deliverable forward FX transactions services. The company has strategic relationships with S&P Dow Jones Indices, LLC; FTSE International Limited; Frank Russell Company; MSCI Inc.; and DJI Opco, LLC. The company was formerly known as CBOE Holdings, Inc. and changed its name to Cboe Global Markets, Inc. in October 2017. Cboe Global Markets, Inc. was founded in 1973 and is headquartered in Chicago, Illinois.
Pressure BioSciences, Inc.
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the Americas, Europe, Asia, Africa, and Australia. Its pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. It serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. Pressure BioSciences, Inc. has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts.
Latest CBOE
- Cboe To Hire Catherine Grover as Executive Vice President and Chief Human Resources Officer
- SEC Form 4 filed by Cboe Global Markets, Inc.
- Cboe Global Markets upgraded by Morgan Stanley with a new price target
- Cboe Global Markets Reports Trading Volume for September 2026
- Cboe Global Markets upgraded by TD Cowen with a new price target
- Wells Fargo initiated coverage on Cboe Global Markets with a new price target
- Cboe Global Markets upgraded by Goldman with a new price target
- Cboe and Robinhood Announce Planned Launch of New KPI Contracts, Further Expanding Prediction Market Offerings
- Cboe Global Markets, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Cboe Provides Additional Details Relating to Anticipated Financial Impacts of S&P DJI Licensing Agreement Extension
Latest PBIO
- SEC Form 10-Q filed by Pressure BioSciences, Inc.
- Director Peterson Jeffrey N acquired $1,670 worth of shares (59,652 units at $0.03), increasing direct ownership by 72% to 142,084 units (SEC Form 4)
- Director Urdea Michael S acquired $404 worth of shares (14,429 units at $0.03), increasing direct ownership by 44% to 47,588 units (SEC Form 4)
- President, CEO Schumacher Richard T acquired $641 worth of shares (22,878 units at $0.03), increasing direct ownership by 38% to 82,967 units (SEC Form 4)
- Director Lazarev Alexander V acquired $528 worth of shares (18,863 units at $0.03), increasing direct ownership by 102% to 37,400 units (SEC Form 4)
- SEC Form 10-Q filed by Pressure BioSciences, Inc.
- SEC Form NT 10-Q filed by Pressure BioSciences, Inc.
- Pressure BioSciences, Inc. filed SEC Form 8-K: Other Events
- Pressure BioSciences, Inc. filed SEC Form 8-K: Leadership Update
- Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET